Matthew Harrison

Voyager Therapeutics Inc (NASDAQ: VYGR) faded this week on news of a CEO transition, but the firm caught a boost Friday from a new advocate. The Rating Morgan Stanley analyst Matthew Harrison initiated coverage of Voyager with an Overweight rating and $36 price target. The Thesis The...

Radius Health Inc (NASDAQ: RDUS) has multiple catalysts that could drive near-term upside in the shares of the company, according to Morgan Stanley.  Radius Health is an integrated biopharma company that specializes in therapies for osteoporosis, oncology and endocrine diseases. The Analyst...

Shares of Juno Therapeutics Inc (NASDAQ: JUNO) soared higher by 50 percent Wednesday after reports surfaced that the company is being targeted by Celgene Corporation (NASDAQ: CELG) for an acquisition. Here's what some of Wall Street's top analysts are saying. Morgan Stanley: Deal Could...

The JPMorgan Healthcare Conference, one of the biggest and most important events of the year for biotech investors, kicks off this week. Last week, Morgan Stanley analyst Matthew Harrison compiled a report on all the things investors should be watching for from the companies attending the...

A Morgan Stanley analyst predicts near-term upside for the shares of Denali Therapeutics Inc. (NASDAQ: DNLI), thanks to its work in neuroscience and particularly its lead programs in Parkinson's and Alzheimer's. The Analyst Morgan Stanley analyst Matthew Harrison initiated coverage of...

Amid the proceedings at the American Society of Hematology's, or ASH, 59th annual meeting, Morgan Stanley highlighted what it views as the biggest potential positive for Celgene Corporation (NASDAQ: CELG). The Analyst Morgan Stanley's Matthew Harrison maintained his Equal-weight...

Global Blood Therapeutics Inc (NASDAQ: GBT), a clinical-stage biopharmaceutical company that focuses on treating blood-based disorders, released results from multiple data presentations during the 59th American Society of Hematology Annual Meeting & Exposition. The Analyst Morgan Stanley'...

The U.S. Food and Drug Administration approved Wednesday Gilead Sciences, Inc. (NASDAQ: GILD)'s therapy for the treatment of non-Hodgkin's Lymphoma (NHL) called YESCARTA. The announcement helped boost Gilead's stock higher by more than 1 percent Thursday, yet some on Wall Street aren't ready to...

Celgene Corporation (NASDAQ: CELG) has gained about 15 percent from its mid-August lows. Against this backdrop of share price appreciation, Morgan Stanley said in a note Thursday that the consensus expectations underappreciate the potential for generic Revlimid as early as April 2020 and the...

Analysts at Morgan Stanley turned bullish on Biogen Inc (NASDAQ: BIIB) as the company's phase 3 Alzheimer's catalyst could "make all its potential issues disappear." The firm's Matthew Harrison upgraded Biogen's stock rating from Equal-Weight to Overweight with a price target boosted from $311 to $...

Shares of bluebird bio Inc (NASDAQ: BLUE) have gained more than 100 percent since the start of 2017 and, more recently, 40 percent on CAR-T "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded...

Sarepta Therapeutics Inc (NASDAQ: SRPT) is trading up more than 20 percent Thursday after a second-quarter beat that included $35 million in sales of its Duchenne muscular dystrophy drug, Exondys 51, against a consensus of $23 million. The Cambridge-based biopharma company has increased its full-...

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced Tuesday that Paul Clancy has been appointed to replace Dave Anderson as CFO, effective July 31. Anderson will remain as a senior advisor through August to ensure a smooth transition. “Paul is well-known among biotech investors, having...

Analysts at Morgan Stanley upgraded Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) Thursday despite the stock's 17-percent loss year to date and two management shake-ups in the past six months alone. Morgan Stanley's Matthew Harrison upgraded Alexion's stock rating from Equal Weight to Overweight...

Morgan Stanley’s Matthew Harrison expects Biogen Inc (NASDAQ: BIIB) to trade in line with the group, after appreciating following the Bioverativ Inc (NASDAQ: BIVV) spinoff and expectations related to Spinraza. The analyst downgraded Biogen from Overweight to Equal-weight, while lowering the...